- Former Chief Commercial Officer at Anacor and Medicis joins leadership team
- Mr. Ippolito has launched over 20 branded medicines in dermatology
- Dermavant has licensed its fourth investigational drug for the treatment of acne
BASEL, Switzerland, September 29, 2017 /PRNewswire/ — Dermavant Sciences, a biopharmaceutical company focused on developing innovative therapies for dermatologic conditions, today announced the appointment of Vince Ippolito as President and Chief Operating Officer.
“I am extremely pleased to welcome Vince Ippolito to the Dermavant team,” said Dr. Jacqualyn A. Fouse, Executive Chair of Dermavant. “Vince brings a tremendous wealth of experience in dermatology. His track record speaks for itself and he has generated significant value for shareholders over the course of his highly successful career.”
“We now have four novel investigational drugs in our pipeline being developed by a highly experienced and dedicated clinical team,” continued Dr. Fouse. “Each compound has the potential to deliver significant value to patients with unmet medical needs in dermatology. It is a perfect time for Vince to join our team and help us take these programs forward.”
Mr. Ippolito has over thirty years of experience in the pharmaceutical industry, including twenty years in dermatology. He most recently served as the Chief Commercial Officer and Executive Vice President of Anacor Pharmaceuticals, a dermatology-focused biopharmaceutical company. At Anacor Mr. Ippolito was responsible for building marketing and sales functions, as well as developing the company’s product portfolio. Prior to Anacor, he was Executive Vice President at Medicis Pharmaceutical, an industry-leading dermatology company.
Over the course of his career, Mr. Ippolito has launched more than twenty brands in dermatology and he has played a leading role in two of the largest dermatology acquisitions of the past five years with combined valuations of $7.8 billion. Mr. Ippolito holds a B.A. in Business Administration, Management, and Operations from the University of Wisconsin with a minor in East Asian Studies from Sophia University in Japan.
“I am thrilled to be joining the Dermavant team and have been very impressed with their focus on bringing much-needed innovation to medical dermatology,” said Mr. Ippolito. “I am excited about the potential in Dermavant’s current pipeline and I look forward to advancing the current compounds in development while also building the pipeline further.”
About Dermavant Sciences
Dermavant Sciences is dedicated to developing and, upon regulatory approval, commercializing innovative therapies in medical dermatology. Dermavant has four clinical-stage drugs in development: RVT-501, RVT-502, RVT-503, and RVT-201.
RVT-501 is a highly potent and selective topical phosphodiesterase-4 inhibitor currently in development for patients with mild-to-moderate atopic dermatitis. RVT-502, also known as cerdulatinib, is a dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor being developed as a topical therapy for a variety of serious dermatologic conditions. RVT-503 is an undisclosed preclinical asset being studied for the treatment of acne. RVT-201 is a caspase-1 inhibitor that acts to inhibit the production of inflammatory cytokines and is being developed for inflammatory skin diseases. For more information, please visit https://www.dermavant.com.